However, a new possibility has emerged: breaking those limits and unlocking a color previously unseen by human eyes. James ...

Paige and Nora Wagner of Duluth don’t share the typical sisterly bond. They’re bonding over what most would see as a situation that could bring anyone down. “I couldn’t see in the dark. So, my mom ...

In honor of Ophthalmology Times’ 50th anniversary, we asked a panel of leading ophthalmologists and optometrists across ...

Today, advancements in medical technology have completely changed how we approach eye care. With faster, more accurate diagnoses and less invasive treatment options, modern eye hospitals are combining ...

ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

A new study published in the journal ACS Pharmacology & Translational Science finds that cannabinoids may offer a promising ...

As opposed to surgery, "an intravitreal injection is one of the simplest procedures in ophthalmology," said the lead ...